NFE2L2 and chronic kidney disease: Although the SOD2 and GPX1 polymorphisms were previously implicated in ESRD development and CKD progression [10,11,15,16], and Nrf-2 in the cardiovascular survival of ESRD patients [7], individually, this is the first study that investigates a combination of these three polymorphisms in ESRD development and the overall or cardiovascular survival with a follow-up of up to 8 years, as well as their association with markers of protein and lipid oxidative damage byproducts, as a possible mechanism.